Compare APT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | MAIA |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 49.3M |
| IPO Year | 1995 | 2022 |
| Metric | APT | MAIA |
|---|---|---|
| Price | $5.25 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.5K | ★ 1.3M |
| Earning Date | 03-11-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $59,096,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.06 | $0.87 |
| 52 Week High | $6.20 | $3.19 |
| Indicator | APT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 49.39 |
| Support Level | $4.96 | $1.69 |
| Resistance Level | $5.64 | $3.19 |
| Average True Range (ATR) | 0.27 | 0.27 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 40.58 | 17.00 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.